Int J Hyperthermia

• 

  Publication Venue For

  • Characterization and initial demonstration of in vivo efficacy of a novel heat-activated metalloenediyne anti-cancer agent..  39:405-413. 2022
  • Editors' awardees for 2022..  39:1124-1125. 2022
  • Editors' awardees for 2021..  38:795-797. 2021
  • The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology..  37:27-34. 2020
  • Editors' awardees for 2020..  37:868-869. 2020
  • Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study..  37:854-860. 2020
  • Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors..  36:74-82. 2019
  • Two questions about the analysis and interpretation of randomised trials..  34:1396-1399. 2018
  • A systematic review of regional hyperthermia therapy in bladder cancer..  32:381-389. 2016
  • Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer..  32:434-445. 2016
  • The use of hyperthermia in the treatment of bladder cancer..  32:349-350. 2016
  • The future of biology in driving the field of hyperthermia..  32:4-13. 2016
  • Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival..  31:386-395. 2015
  • Systemic anti-tumour effects of local thermally sensitive liposome therapy..  30:385-392. 2014
  • Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer..  30:285-294. 2014
  • A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer..  30:166-170. 2014
  • A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer..  30:171-175. 2014
  • Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer..  30:176-183. 2014
  • Magnetic fluid hyperthermia for bladder cancer: a preclinical dosimetry study..  29:835-844. 2013
  • A method to convert MRI images of temperature change into images of absolute temperature in solid tumours..  29:569-581. 2013
  • A role for the copper transporter Ctr1 in the synergistic interaction between hyperthermia and cisplatin treatment..  29:528-538. 2013
  • Actively targeting solid tumours with thermoresponsive drug delivery systems that respond to mild hyperthermia..  29:501-510. 2013
  • The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment..  29:206-210. 2013
  • Miniature microwave applicator for murine bladder hyperthermia studies..  28:456-465. 2012
  • Thermal dose fractionation affects tumour physiological response..  28:431-440. 2012
  • Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound..  27:140-155. 2011
  • Hyperthermic effects on behavior..  27:353-373. 2011
  • Improved hyperthermia treatment control using SAR/temperature simulation and PRFS magnetic resonance thermal imaging..  27:86-99. 2011
  • Non-invasive, quantitative monitoring of hyperthermia-induced EGFR activation in xenograft tumours..  27:427-434. 2011
  • Sensing hot and cold with TRP channels..  27:388-398. 2011
  • Thresholds for thermal damage to normal tissues: an update..  27:320-343. 2011
  • A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer..  26:514-521. 2010
  • Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours..  26:485-498. 2010
  • Conformal microwave array (CMA) applicators for hyperthermia of diffuse chest wall recurrence..  26:686-698. 2010
  • Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data..  26:612-617. 2010
  • Hyperthermia for locally advanced breast cancer..  26:618-624. 2010
  • Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer..  26:625-637. 2010
  • Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy..  26:283-293. 2010
  • Hyperthermia classic commentary: 'Arrhenius relationships from the molecule and cell to the clinic' by William Dewey, Int. J. Hyperthermia, 10:457-483, 1994..  25:21-24. 2009
  • DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study..  25:405-415. 2009
  • Hyperthermia MRI temperature measurement: evaluation of measurement stabilisation strategies for extremity and breast tumours..  25:422-433. 2009
  • Radiofrequency ablation: the effect of distance and baseline temperature on thermal dose required for coagulation..  24:550-559. 2008
  • Hyperthermia and nanotechnology - a note from the Editor-in-chief..  24:449-450. 2008
  • Tumor microvascular permeability is a key determinant for antivascular effects of doxorubicin encapsulated in a temperature sensitive liposome..  24:475-482. 2008
  • First international association of hyperthermic oncology Tsudomu Sugahara award..  24:442-443. 2008